-
1
-
-
72049130805
-
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
-
Jack CR Jr, Knopman D, Jagust W, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
-
(2010)
Lancet Neurol.
, vol.9
, pp. 119-128
-
-
Jack Jr., C.R.1
Knopman, D.2
Jagust, W.3
-
2
-
-
0028169925
-
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42 43
-
Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53
-
(1994)
Neuron
, Issue.13
, pp. 45-53
-
-
Iwatsubo, T.1
Odaka, A.2
Suzuki, N.3
-
3
-
-
84655162704
-
Soluble Abeta oligomer production and toxicity
-
Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem 2012;120(Suppl 1):125-39
-
(2012)
J. Neurochem.
, vol.120
, Issue.SUPPL.1
, pp. 125-139
-
-
Larson, M.E.1
Lesne, S.E.2
-
4
-
-
84880189986
-
Immunotherapy for Alzheimer's disease
-
Morgan D. Immunotherapy for Alzheimer's disease. J Alzheimers Dis 2006;9:425-32
-
(2006)
J. Alzheimers Dis.
, vol.9
, pp. 425-432
-
-
Morgan, D.1
-
5
-
-
79959670013
-
The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
-
Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31:9323-31
-
(2011)
J. Neurosci.
, vol.31
, pp. 9323-9331
-
-
Wiessner, C.1
Wiederhold, K.H.2
Tissot, A.C.3
-
6
-
-
77956206153
-
Vaccination therapy for Alzheimer's disease
-
Tabira T. Vaccination therapy for Alzheimer's disease. Rinsho Shinkeigaku 2009;49:848-50
-
(2009)
Rinsho Shinkeigaku
, vol.49
, pp. 848-850
-
-
Tabira, T.1
-
7
-
-
0033536163
-
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
-
Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
-
(1999)
Nature
, vol.400
, pp. 173-177
-
-
Schenk, D.1
Barbour, R.2
Dunn, W.3
-
8
-
-
0034700471
-
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
-
Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-82
-
(2000)
Nature
, vol.408
, pp. 979-982
-
-
Janus, C.1
Pearson, J.2
McLaurin, J.3
-
9
-
-
0035106780
-
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
-
Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72
-
(2001)
Nat. Med.
, vol.7
, pp. 369-372
-
-
Bacskai, B.J.1
Kajdasz, S.T.2
Christie, R.H.3
-
16
-
-
73349091534
-
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
-
Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
-
(2009)
Neurology
, vol.73
, pp. 2061-2070
-
-
Salloway, S.1
Sperling, R.2
Gilman, S.3
-
17
-
-
77949300796
-
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study
-
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
-
(2010)
Lancet Neurol.
, vol.9
, pp. 363-372
-
-
Rinne, J.O.1
Brooks, D.J.2
Rossor, M.N.3
-
18
-
-
77951086901
-
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
-
Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
-
(2010)
Clin. Neuropharmacol.
, vol.33
, pp. 67-73
-
-
Siemers, E.R.1
Friedrich, S.2
Dean, R.A.3
-
19
-
-
84862777153
-
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis
-
Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 2012;11:241-9
-
(2012)
Lancet Neurol.
, Issue.11
, pp. 241-249
-
-
Sperling, R.1
Salloway, S.2
Brooks, D.J.3
-
20
-
-
58149129243
-
Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain
-
Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299-310
-
(2008)
Brain
, vol.131
, pp. 3299-3310
-
-
Boche, D.1
Zotova, E.2
Weller, R.O.3
-
21
-
-
65649148265
-
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice
-
Wilcock DM, Colton CA. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 2009;8:50-64
-
(2009)
CNS Neurol Disord Drug Targets
, vol.8
, pp. 50-64
-
-
Wilcock, D.M.1
Colton, C.A.2
-
22
-
-
49049089830
-
Immunotherapy reduces vascular amyloid-beta in PDAPP mice
-
Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28:6787-93
-
(2008)
J. Neurosci.
, vol.28
, pp. 6787-6793
-
-
Schroeter, S.1
Khan, K.2
Barbour, R.3
-
23
-
-
79960817113
-
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's association research roundtable workgroup
-
Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Demen 2011;7:367-85
-
(2011)
Alzheimers Demen.
, vol.7
, pp. 367-385
-
-
Sperling, R.A.1
Jack Jr., C.R.2
Black, S.E.3
-
24
-
-
84863115941
-
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
-
Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207
-
(2012)
Arch. Neurol.
, Issue.69
, pp. 198-207
-
-
Ostrowitzki, S.1
Deptula, D.2
Thurfjell, L.3
-
25
-
-
84855780598
-
Gantenerumab: A novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta
-
Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: A novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012;28:49-69
-
(2012)
J. Alzheimers Dis.
, Issue.28
, pp. 49-69
-
-
Bohrmann, B.1
Baumann, K.2
Benz, J.3
-
26
-
-
58149401811
-
Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice
-
Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 2008;28:14156-64
-
(2008)
J. Neurosci.
, vol.28
, pp. 14156-14164
-
-
Koenigsknecht-Talboo, J.1
Meyer-Luehmann, M.2
Parsadanian, M.3
-
28
-
-
10744230547
-
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
-
Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
-
(2003)
Neurology
, vol.61
, pp. 46-54
-
-
Orgogozo, J.M.1
Gilman, S.2
Dartigues, J.F.3
-
29
-
-
20944448555
-
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
-
Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
-
(2005)
Neurology
, vol.64
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.S.3
-
30
-
-
77951851348
-
Pre-dementia Alzheimer's trials: Overview
-
Aisen PS. Pre-dementia Alzheimer's trials: Overview. J Nutr Health Aging 2010;14:294
-
(2010)
J. Nutr. Health Aging
, vol.14
, pp. 294
-
-
Aisen, P.S.1
-
31
-
-
77951780844
-
Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease
-
Cedarbaum JM, Crans G, Grundman M. Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease. J Nutr Health Aging 2010;14:306-9
-
(2010)
J. Nutr. Health Aging
, vol.14
, pp. 306-309
-
-
Cedarbaum, J.M.1
Crans, G.2
Grundman, M.3
-
33
-
-
35348981740
-
Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide
-
Hayashi T, Shishido N, Nakayama K, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 2007;43:1552-9
-
(2007)
Free Radic. Biol. Med.
, vol.43
, pp. 1552-1559
-
-
Hayashi, T.1
Shishido, N.2
Nakayama, K.3
-
34
-
-
35948936850
-
Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron
-
Nakamura M, Shishido N, Nunomura A, et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 2007;46:12737-43
-
(2007)
Biochemistry
, vol.46
, pp. 12737-12743
-
-
Nakamura, M.1
Shishido, N.2
Nunomura, A.3
-
37
-
-
33646855957
-
Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic
-
Castellani RJ, Lee HG, Zhu X, et al. Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic. Acta Neuropathol 2006;111:503-9
-
(2006)
Acta. Neuropathol.
, vol.111
, pp. 503-509
-
-
Castellani, R.J.1
Lee, H.G.2
Zhu, X.3
-
38
-
-
34248560960
-
Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses
-
Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses. J Pharmacol Exp Ther 2007;321:823-9
-
(2007)
J. Pharmacol. Exp. Ther.
, vol.321
, pp. 823-829
-
-
Lee, H.G.1
Zhu, X.2
Castellani, R.J.3
-
39
-
-
0037264969
-
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
-
Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62
-
(2003)
Nat. Rev. Drug Discov.
, vol.2
, pp. 52-62
-
-
Brekke, O.H.1
Sandlie, I.2
-
40
-
-
77953282150
-
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
-
Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
-
(2010)
Alzheimer Dis. Assoc. Disord.
, vol.24
, pp. 198-203
-
-
Black, R.S.1
Sperling, R.A.2
Safirstein, B.3
-
41
-
-
84855854663
-
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease
-
Uenaka K, Nakano M, Willis BA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 2012;35:25-9
-
(2012)
Clin. Neuropharmacol.
, Issue.35
, pp. 25-29
-
-
Uenaka, K.1
Nakano, M.2
Willis, B.A.3
-
42
-
-
19944431509
-
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta
-
Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
-
(2005)
J. Neurosci.
, vol.25
, pp. 629-636
-
-
Racke, M.M.1
Boone, L.I.2
Hepburn, D.L.3
-
43
-
-
84863750982
-
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
-
Epub ahead of print].
-
Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer Disease. Arch Neurol 2012. [Epub ahead of print].
-
(2012)
Arch. Neurol.
-
-
Blennow, K.1
Zetterberg, H.2
Rinne, J.O.3
|